Inflammatory bowel disease and mucosal barrier disorders — indication assessment

§1Assessment

§1.1Definition

Chronic immune-mediated inflammation of the intestinal tract, or disorders of intestinal permeability including coeliac disease.

§1.2Anchor and additional outcomes

The Institute designates one anchor outcome per indication so that estimates for different compounds are reported on a common measure. The anchor for this indication is the first outcome below.

1. Clinical remission
2. Endoscopic healing
3. Faecal calprotectin
4. Intestinal permeability by lactulose–mannitol ratio

§1.3State of the evidence

The Institute assesses 4 compounds in this indication, drawing on 27 trial records and 6 evidence syntheses. ^[1,2]

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

1. D’Hondt M, Bracke N, Taevernier L, Gevaert B, Verbeke F, Wynendaele E, De Spiegeleer B. Related impurities in peptide medicines. Journal of Pharmaceutical and Biomedical Analysis 2014;101:2–30. doi:10.1016/j.jpba.2014.06.012 · PMID 25044089
2. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MS, Eldridge SM, Emberson JR, Hernán MA, Hopewell S, Hróbjartsson A, Junqueira DR, Jüni P, Kirkham JJ, Lasserson T, Li T, McAleenan A. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 2019;366:l4898. doi:10.1136/bmj.l4898 · PMID 31462531

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.